Screening for cervical carcinoma and a number of infections of the female genital tract including human papillomavirus, herpes, Candida, and Trichomonas
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CVSPC | Physician Interp Conventional | No | No |
Light Microscopy
Cervical Papanicolaou Smear, Diagnostic
CPAPD
Pap Smear
Varies
Laboratory approval prior to ordering cytology testing is required
Specimen submitted as endocervical curettage or endocervical brushing must be ordered as CYTNG/ Cytology Non-Gynecologic.
1. An acceptable cytology request form must accompany specimen containers and include the following: Patient's name, medical record number, date of birth, sex, source (exact location and procedure used), date specimen was taken, name of ordering physician and pager number.
2. Submit any pertinent clinical information, including date of last menstrual period.
Question ID | Description | Answers |
---|---|---|
CY037 | Pap Smear Test |
Cervical/Endocervical Vaginal |
CY038 | Clinical History | |
CY039 | Menstrual Status (LMP, PM, Pregnant) | |
CY040 | Hormone Therapy/Contraceptives |
None/Not known Oral Contraceptives Depoprovera IUD Hormone Replacement Therapy |
Patient Preparation: For optimal interpretation, Papanicolaou smears should be collected near the middle of the menstrual cycle. No douching, lubricant use, or sexual intercourse for 24 hours prior to specimen collection.
Container/Tube: Slide
Specimen Volume: Circular scrape of cervical os
Collection Instructions:
1. Specimen containers must be labeled with a minimum of 2 unique identifiers (patient's name, and medical record number or date of birth). Containers should also be labeled with specimen source, and date collected.
2. Glass slides may be labeled with a single unique identifier, but 2 identifiers are preferred. If multiple slides are submitted, each slide must have proper identification. Glass slides should be identified with the patient's name and a second patient identifier that is also on the accompanying paperwork (ie, medical record number or date of birth)
3. Fix slides immediately in 95% alcohol or treat with commercially available spray fixative.
SurePath vial | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | SLIDE | |
Refrigerated | SLIDE |
Screening for cervical carcinoma and a number of infections of the female genital tract including human papillomavirus, herpes, Candida, and Trichomonas
Squamous cell carcinoma of the cervix is believed to develop in progressive stages from normal through precancerous (dysplastic) stages, to carcinoma in situ, and eventually invasive carcinoma. This sequence is felt to develop over a matter of years in most patients.
The etiology of cervical carcinoma is unknown, but the disease is believed to be related to sexual activity and possibly sexually transmitted viral infections such as human papillomavirus (HPV).
Most cervical carcinomas and precancerous conditions occur in the transformation zone (squamo-columnar junction), therefore, this area needs to be sampled if optimum results are to be obtained.
Satisfactory for evaluation. Negative for intraepithelial lesion or malignancy.
Note: Abnormal results will be reviewed by a physician at an additional charge.
Standard reporting, as defined by the Bethesda System (TBS) is utilized.
If endocervical cells have not been obtained (less than optimal smears) the results may be unreliable.
There is a false-negative rate of 10% to 20% in the presence of cervical intraepithelial neoplasia or invasive squamous cell carcinoma.
The Papanicolaou test is unreliable for endometrial carcinoma (at least 50% false-negative rate).
1. Wright TC Jr, Cox JT, Massad LS, et al: ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002 April;287(16):2120-2129
2. Solomon D, Davey D, Kurman R, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology-Consensus Statement JAMA. 2002 April;287(16):2114-2119
Papanicolaou-stained slides are microscopically examined by a cytotechnologist. Abnormal findings are reviewed and reported by a pathologist (charged separately).(Unpublished Mayo method)
Monday through Friday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
P3000
88164
88141-CVSPC (if appropriate)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
CPAPD | Conventional Smear-Diagnostic | In Process |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
71306 | Interpretation | 59465-5 |
71307 | Participated in the Interpretation | No LOINC Needed |
71308 | Report electronically signed by | 19139-5 |
71309 | Addendum | 35265-8 |
71310 | Gross Description | 22634-0 |
CY037 | Pap Test Source | 19763-2 |
CY038 | Clinical History | 22636-5 |
CY039 | Menstrual Status (LMP, PM, Pregnant) | 8678-5 |
CY040 | Hormone Therapy/Contraceptives | 8659-5 |
71573 | Disclaimer | 62364-5 |
71819 | Case Number | 80398-1 |